What: Specialty Drug Webinar on Biosimilars
When: January 27, 2016 from 2 – 3 PM (EST)
Click Here to REGISTER NOW – Seats are Limited!
Join RJ Health Systems for the first in a series of two webinars focusing on Biosimilars and what effect they will have on the Specialty Drug Industry. “Biosimilars – State of the Market” will be hosted by RJ’s own Randy Falkenrath on Wednesday, January 27, 2016 at 2:00 PM (EST).
In this webinar, we will share detailed insights on the investments and status of the biosimilar pipeline, the regulatory challenges and early experience and lessons learned from Zarxio (filgrastim-sndz) the first approved biosimilar in the U.S. To date, six biologics 351(k) license applications (see chart) have been filed to legally market a biosimilar or interchangeable biological product in the U.S.
To learn more about Biosimilars or talk to one of our experts, please email us at info@reimbursementcodes.com.
All, Company Updates, Educational Resources
Biosimilars: State of the Market
21
Jan
Jan
What: Specialty Drug Webinar on Biosimilars
When: January 27, 2016 from 2 – 3 PM (EST)
Click Here to REGISTER NOW – Seats are Limited!
Join RJ Health Systems for the first in a series of two webinars focusing on Biosimilars and what effect they will have on the Specialty Drug Industry. “Biosimilars – State of the Market” will be hosted by RJ’s own Randy Falkenrath on Wednesday, January 27, 2016 at 2:00 PM (EST).
In this webinar, we will share detailed insights on the investments and status of the biosimilar pipeline, the regulatory challenges and early experience and lessons learned from Zarxio (filgrastim-sndz) the first approved biosimilar in the U.S. To date, six biologics 351(k) license applications (see chart) have been filed to legally market a biosimilar or interchangeable biological product in the U.S.
To learn more about Biosimilars or talk to one of our experts, please email us at info@reimbursementcodes.com.
